Tango Therapeutics (NASDAQ:TNGX – Free Report) had its price target lowered by Guggenheim from $16.00 to $14.00 in a report published on Friday, Benzinga reports. The firm currently has a buy rating on the stock. Several other research analysts have also issued reports on TNGX. Barclays lowered their target price on Tango Therapeutics from $18.00 […]
HC Wainwright reiterated their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a research note issued to investors on Friday, Benzinga reports. HC Wainwright currently has a $65.00 price target on the biotechnology company’s stock. Several other brokerages have also recently weighed in on MRUS. William Blair restated an outperform rating on […]
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month […]
Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month […]
Tango Therapeutics (NASDAQ:TNGX – Free Report) had its price target lowered by Barclays from $18.00 to $13.00 in a report published on Friday, Benzinga reports. The firm currently has an overweight rating on the stock. Other research analysts also recently issued reports about the company. Wedbush cut their target price on Tango Therapeutics from $18.00 […]